InnoCare Advances Vitiligo Drug After Phase 2 Result

InnoCare's TYK2 inhibitor soficitinib hits vitiligo Phase 2 endpoint, advancing to Phase 3. Competitive autoimmune skin disorder trial shows strong F-VASI improvement.

Linsey Smith

Jul 16, 2026

1 min read

InnoCare Pharma said its TYK2 inhibitor soficitinib met the primary endpoint in the phase 2 portion of a trial in people with nonsegmental vitiligo, allowing the biotech to move into the phase 3 stage of the study.

The 24-week trial, conducted at sites in China, measured changes in the Facial Vitiligo Area Scoring Index, or F-VASI. Patients receiving the higher soficitinib dose recorded a 41.2% change from baseline, compared with 38.8% for the lower dose and 2.2% for placebo. Both doses performed significantly better than placebo, according to the company’s topline results.

Vitiligo is an autoimmune skin disorder in which areas of skin lose pigment. The result places InnoCare in a competitive market. Incyte’s Opzelura is already approved by the U.S. Food and Drug Administration for vitiligo, while Takeda is testing its own TYK2 inhibitor, zasocitinib, in a phase 2 trial.

InnoCare said the treatment was well tolerated and that no new safety signals emerged. But the company has not released detailed safety data or additional efficacy results. It said those findings will be presented at a scientific congress or published in an academic journal.

The drug, also called ICP-332, is under study in several other inflammatory skin conditions, including atopic dermatitis, chronic spontaneous urticaria, plaque psoriasis and prurigo nodularis.

The phase 2 result is encouraging, but it is not approval. The ongoing phase 3 portion will be pivotal in establishing the drug’s benefit-risk profile and its commercial position in vitiligo.

#AIInClinicalTrials # Drugstudies

About the Writer

Linsey Smith

0 MPXR

What can I say about my Linsey eh?I am Linsey-The Ember-Clad Blade. They called me Linsey before I earned a title. Before the fire in my chest burned brighter than the sun over Ashgard. I was born in the slums beneath the Sky Spires—where iron dust chokes the breath and mothers trade sleep for the silence of safety. My hands learned to fight long before they learned to write. But even then, I didn’t dream of escape. I dreamt of dominion. Of not just surviving the cruelty of the world, but folding it into my will.By sixteen, I’d severed ties with mercy. Steel answered my every question. I fought in the arenas of Vyrn for coin and for pride, and when they told me a girl couldn’t rise, I slit their myths open at the throat. But rage wasn’t all I was. There was elegance in how I moved—an unspoken rhythm, like my blade and body danced together. I never wanted to be feared. I wanted to be respected. There’s a difference, and I carved it out with every duel I won standing tall.Now they whisper stories of the Ember-Clad Blade—the girl who scorched her past and forged herself into something divine. I walk alone, yes, but not empty. The weight of my choices sits with me like a second spine. Call me warrior, call me witch, call me whatever your trembling voice decides. Just know this: I fight for the ones who are never heard, and I burn for the girls still dreaming in the dark.

Keep reading

Three more ideas worth your time.

Browse MindBytes

Discussion

Join the discussion

Type @ to mention someone Type / or use + to add a block Highlight text, then choose Link

Loading editor

Comments cannot be edited after posting because they become part of the reputation record. Give yours a quick review first.